GlassScriptPhysician profile
Saman Safadjou
NPI 1255696795
$4,327.71
in general payments reported to CMS, 2019-2025
11 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $2,406 · 2021: $176 · 2022: $276 · 2023: $539 · 2024: $427 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,658.84 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $962.83 | 2020 | |
| Endologix LLC | $520.60 | 2021-2024 | Endocross Device, Torus Stent Graft System, Alto Abdominal Stent Graft System |
| Medtronic, INC. | $457.27 | 2021-2025 | Endurant Iis |
| W. L. Gore & Associates, INC. | $363.58 | 2023-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis, Gore Tag Conformable Thoracic Endoprosthesis |
| Boston Scientific Corporation | $174.11 | 2022-2023 | |
| Silk Road Medical, INC. | $125.14 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Scpharmaceuticals INC. | $23.35 | 2025 | |
| Merck Sharp & Dohme LLC | $15.27 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $13.44 | 2023 | Arcalyst |
| Inari Medical, INC. | $13.28 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saman Safadjou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.